Terry Smith

Former scientist. Penn State PhD/MBA 2006. Professional small/mid cap biotech investor.

[Terry Smith @TerryMSmith]

@given2tweet This transcript has the end. Didn't miss anything but not abrupt.

[Terry Smith @TerryMSmith]

@avidresearch no preconditioning for beam on this one. weakness of beam is that it is permanent and is making functional but not wild type protein.

[Terry Smith @TerryMSmith]

@avidresearch @greybio1 @PositiveTopline @LetMeFireASAP So FA patients have 10-20% of unaffected people's FXN levels. Getting to 50% is curative. Assume they were 15% at baseline, 125% of baseline means they are now at 19% of normal. I guess phase 3 will tell us if 19% of normal results in a clinical benefit compared to 15% of normal.

[Terry Smith @TerryMSmith]

@given2tweet for $AVDL CVR to pay, this needs to be approved by end of 2028. Positive phase 3 data this morning. https://t.co/M0MWrDMxUx

[Terry Smith @TerryMSmith]

@BrainDonor @Kid_From_Bklyn @adamfeuerstein I think the transfer price is too low and the ASP will be the transfer price instead of the final price that they want. As such, doctors will be reimbursed ASP plus 6 and they will be massively underwater and can't administer it.

[Terry Smith @TerryMSmith]

@adamfeuerstein https://t.co/ZWDjYcOeoY

[BaffledBiologist @BlaseBio]

Hey wakeup, a new Makary meme just dropped

[Terry Smith @TerryMSmith]

@RxRegA I think the briefing docs were really harsh. I remember a big stock drawdown in there and I think the docs were the cause.

[Terry Smith @TerryMSmith]

@avidresearch Chemocentryx. $CCXI

[Terry Smith @TerryMSmith]

@AppleHelix @plainyogurt21

[Terry Smith @TerryMSmith]

@adamfeuerstein @ADeAngelis_bio When cosmo reported percent change, it wasn’t percent change from baseline, it was how much more hair growth there was in treatment arm than the placebo arm for that trial.

[Terry Smith @TerryMSmith]

@John_Hempton @adamfeuerstein @DmitryKovalchuk

[Terry Smith @TerryMSmith]

@John_Hempton @adamfeuerstein @DmitryKovalchuk Seems that REGN owend 8.6% of the company when it came public, they owed $35M per project and were on the hook for half of dev costs. Interestingly no rev projections with the deal background. https://t.co/vOQMIxmTwO https://t.co/akVGcPIlAF

[Terry Smith @TerryMSmith]

@Sanctuary_Bio @adamfeuerstein I haven't looked at it either. Seems they were on the hook with a partership. The gene therapy market has fallen apart since they acquired it. They at least get a PRV and some good will for giving away a drug for free that will get near zero utilization.

[Terry Smith @TerryMSmith]

@Sanctuary_Bio @adamfeuerstein prv?

[Terry Smith @TerryMSmith]

@nociFTW *shrug*. technical term.

[Brad Loncar @bradloncar]

@silvertrade I hate to even comment on such a serious thing because only the safety of people matters, but FWIW I asked Teva’s CEO about their operations in Israel earlier this month and he said Israel is less than 8% of their manufacturing. https://t.co/5OoVV1K7TT

[Terry Smith @TerryMSmith]

@AppleHelix here is the study they had to do to get the DPI approved. https://t.co/LkhkIOrJbj

[Terry Smith @TerryMSmith]

@RNAiAnalyst but OTC in the US is cash pay out of pocket--generally not covered by insurance as the system exists right now.